Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions

Drug Metabolism and Disposition

Volumn 27, Issue 9, 1999, Pages 1029-1038

  Vickers, Alison E M ^a   Sinclair, John R ^b   Zollinger, Markus ^b   Heitz, Francis ^b   Glänzel, Ulrike ^b   Johanson, Laurie ^a   Fischer, Volker ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FURAFYLLINE; N DEMETHYLASE; PYRROLE DERIVATIVE; TERBINAFINE; TROLEANDOMYCIN;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DEAMINATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME METABOLISM; HUMAN; HUMAN CELL; KINETICS; LIVER MICROSOME; MICHAELIS CONSTANT; OXIDATION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; ISOENZYMES; KINETICS; MASS SPECTROMETRY; NAPHTHALENES; RECOMBINANT PROTEINS;

EID: 0032870308     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Back DJ, Stevenson P and Tija JF (1989) Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporine and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 28:166-170.
2. Back DJ, Tija JF and Abel SM (1992) Azoles, allylamines and drug metabolism. Br J Dermatol 126 (Suppl 39):14-18.
3. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
4. Ball SE, Maurer G, Zollinger M, Ladona M and Vickers AEM (1992) Characterization of the cytochrome P-450 gene family responsible for V-dealkylation of the ergot alkaloid CQA 206-291 in humans. Drug Metab Dispos 20:56-63.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Chang TK, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-442.
7. Cramer JA, Robbins B, Barbeito R, Bedman TC, Dreisbach A and Meligeni JA (1996) Lamisil: Interaction study with a sustained release nifedipine formulation. Pharm Res 13 (Suppl 9):436.
8. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235.
9. Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV and Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259.
10. Engel G, Hofmann U, Heidemann H, Cosme J and Eichelbaum M (1996) Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxy, 3-hydroxymethyl-and norantipyrine formation. Clin Pharmacol Ther 50:613-623.
11. Ferguson RM, Sutherland DER, Simmons RL and Najarian JS (1982) Ketoconazole, cyclosporine metabolism and renal transplantation. Lancet 2:882-883.
12. Fischer V, Rodríguez-Gascón A, Heitz F, Tynes R, Hauck C, Cohen D and Vickers AEM (1998) The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26:802-811.
13. Fischer V, Vickers AEM, Heitz F, Mahadevan S, Baldeck J-P, Minery P and Tynes R (1994) The polymorphic cylochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 22:269-274.
14. i values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
15. Guerret M, Francheteau P and Hubert M (1997) Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Pharmacotherapy 17:767-773.
16. Humbert H, Cabiac MD, Denouél J and Kirkesseli S (1995) Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm Drug Dispos 16:685-694.
17. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
18. Jensen JC (1989) Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 14: 110-113.
19. Jensen JC (1990) Pharmacokinetics of Lamisil in humans. J Derm Treatment 1 (Suppl 2):15-18.
20. Klotz U and Reimann I (1983) Effect of histamine H2-receptor antagonists on the hepatic elimination of drugs. Klin Wochenschr 61:625-632.
21. Koymans L, Vermeulen NPE, van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsen K, Meuldermans W and den Kelder GMD (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211-219.
22. Kronbach T, Fischer V and Meyer UA (1988) Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43:630-635.
23. Lazar JD and Wilner KD (1990) Drug interactions with fluconazole. Rev Infect Dis 12 (Suppl 3): s327-s333.
24. Leeder JS, Gotschall RR, Gaedigk A and Kearns GL (1998) CYP2D6 phenotype-genotype discordance and potential new drug-drug interactions (Abstract PIII-37). Clin Pharmacol Ther 63:216.
25. Long CC, Hill SA, Thomas RC, Johnston A, Smith SG, Kendall F and Finlay AY (1994) Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. J Invest Dermatol 102:740-743.
26. Omura T and Sato R (1964) The carbon-monoxide binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
27. Olkkola KT, Backmann JT and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
28. Robbins BA, Chang C-T, Cramer JA, Gareffa S, Hafkin B, Hunt TL and Meligeni JA (1996) Safe coadministration of terbinafine and terfenadine: A placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clin Pharmacol Ther 59:275-283.
29. Ryder NS (1989) The mechanism of action of terbinafine. Clin Exp Dermatol 14:110-113.
30. Schuster I (1987) Metabolic degradation of terbinafine in liver microsomes from man, guinea pig and rat, in Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents (Fromtling RA ed) pp 461-470, JR Prous Science Publishers, Barcelona.
31. Segel IH (1993) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, pp 161-226, John Wiley & Sons, New York.
32. Seyffer R, Eichelbaum M, Jensen JC and Klotz U (1989) Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol 37:231-233.
33. Shah IA, Whiting PH, Omar G, Ormerod AD and Burke MD (1993) The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin. Br J Dermatol 129:395-398.
34. Shepard JH, Canafax DM, Simmons RL and Najarian JS (1986) Cyclosporine-ketoconazole: A potentially dangerous drug-drug interaction. Clin Pharm 5:468.
35. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994). J Pharmacol Exp Ther 270:414-423.
36. Smith AG (1984) Potentiation of oral anticoagulants by ketoconazole. Br Med J 288:188-189.
37. Sorkin EM and Heel RC (1985) Terfenadine: A review of its pharmaco-dynamic properties and therapeutic efficacy. Drugs 29:34-56.
38. Trepanier EF, Nafziger AN and Amsden GW (1998a) Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 42:695-697.
39. Trepanier EF, Nafziger AN, Kearns GL, Kashuba AD and Amsden GW (1998b) Absence of effect of terbinafine on the activity of CYP1A2, NAT-2 and xanthine oxidase. J Clin Pharmacol 38:424-428.
40. Van den Bossche H, Willemsens G, Cools W, Cornelissen F, Lauwers WF and van Cutsem JM (1980) In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 17:922-928.
41. Van den Bossche H, Willemsens G, Cools W, Lauwers WF and LeJeune L (1978) Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans. Chem Biol Interact 21:59-78.
42. Van der Kuy P-HM, Hooymans PM and Verkaaik AJB (1998) Nortriptyline intoxication induced by terbinafine. BMJ 314:441.
43. Varhe A, Olkkola KT and Neuvonen PJ (1996) Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 41:319-323.
44. Wahllander A and Paumgartner G (1989) Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol 37:279-283.